BioLife Solutions (BLFS) announced the acquisition of privately-held PanTHERA CryoSolutions, a developer of novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor technology. The acquisition further strengthens BioLife’s position as the market leader in biopreservation, enhancing its product portfolio of consumable solutions and adds scientific capabilities to the management team. BioLife is purchasing the 90% of PanTHERA common shares it does not own for $9.3M in cash and 241,355 shares of BioLife Common stock. PanTHERA’s shareholders are also eligible to receive up to an additional $7.2M of BioLife common stock over the next three years contingent on the achievement of certain scientific and revenue milestones.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLFS:
- BioLife Solutions price target raised to $30 from $27 at H.C. Wainwright
- BioLife Solutions: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
- BioLife Solutions Inc.: Focus on Growth Over Dividends May Limit Immediate Investor Returns
- BioLife Solutions Reports Strong 2024 Financial Growth
- BioLife Solutions Inc. Projects Strong 2025 Growth